Bian Wei, Xu Zhishun
Department of Urology, QiLu Hospital of ShanDong University, Jinan, Shandong Province, China.
Int J Urol. 2007 Feb;14(2):108-11. doi: 10.1111/j.1442-2042.2007.01670.x.
CYFRA21-1, telomerase and vascular endothelial growth factor (VEGF) are regarded as useful tumor markers in the detection of bladder transitional cell carcinoma. However, the sensitivity of each single marker seemed to be unsatisfactory. In the current study, we assessed the sensitivity of the combined assay of these three markers in the detection of human bladder transitional cell carcinoma.
Voided urine samples of 100 patients with bladder transitional cell carcinoma were obtained and each sample was aliquoted for the various assay. Urinary CYFRA21-1 and VEGF were detected by enzyme-linked immunosorbent assay and telomerase detected by the telomeric repeat amplification protocol. The sensitivity of combined assay was compared to that of each single marker and urinary cytology, respectively.
In the 100 patients, the sensitivity was 74% for urinary CYFRA21-1, 71% for telomerase, 69% for VEGF, and 38% for cytology. CYFRA21-1, telomerase and VEGF proved significantly more sensitive than cytology, respectively (P = 0.000). The sensitivity of the combined assay in the current study was 94% and it was significantly higher than that of cytology, urinary telomerase, CYFRA21-1 or VEGF (P = 0.000). In 50 patients with hematuria but without bladder cancer, the overall specificity of the assays was 78% for CYFRA21-1, 84% for telomerase, 88% for VEGF, and 92% for cytology.
Combined assay of the markers which show different characteristics of the tumor behaviors seemed to be of interest in the detection of bladder transitional cell carcinoma.
细胞角蛋白19片段(CYFRA21-1)、端粒酶和血管内皮生长因子(VEGF)被视为检测膀胱移行细胞癌的有用肿瘤标志物。然而,单一标志物的敏感性似乎并不理想。在本研究中,我们评估了这三种标志物联合检测在人类膀胱移行细胞癌检测中的敏感性。
收集100例膀胱移行细胞癌患者的晨尿样本,每份样本均分为若干份用于各种检测。采用酶联免疫吸附测定法检测尿CYFRA21-1和VEGF,采用端粒重复序列扩增法检测端粒酶。将联合检测的敏感性分别与单一标志物及尿细胞学检查的敏感性进行比较。
在100例患者中,尿CYFRA21-1的敏感性为74%,端粒酶为71%,VEGF为69%,细胞学检查为38%。CYFRA21-1、端粒酶和VEGF的敏感性均显著高于细胞学检查(P = 0.000)。本研究中联合检测的敏感性为94%,显著高于细胞学检查、尿端粒酶、CYFRA21-1或VEGF(P = 0.000)。在50例血尿但无膀胱癌的患者中,CYFRA21-1检测的总体特异性为78%,端粒酶为84%,VEGF为88%,细胞学检查为92%。
联合检测具有不同肿瘤行为特征的标志物在膀胱移行细胞癌检测中似乎具有重要意义。